OS by treatment group in NPM1⁺patients treated with HMA + VEN, HMA, and IC. (A) OS was not significantly different between HMA + VEN vs IC when patients of all ages were included in the analysis (median OS, NR vs 3.7 years; P = .292). (B) However, in patients age >65 years, HMA + VEN demonstrated a significant improvement in OS compared with IC (median OS, NR vs 0.9 years; P < .001). HMA + VEN outperformed HMA monotherapy, which demonstrated a median OS of 0.4 years (4.8 months).